
  
    
      
        Background_NNP
        Although_IN a_DT number_NN of_IN recently_RB introduced_VBN
        chemotherapeutic_JJ agents_NNS have_VBP demonstrated_VBN significant_JJ
        anti-tumor_JJ activity_NN in_IN advanced_JJ colorectal_NN cancer_NN ,_, [_NN 1_CD 2_CD 3_CD
        4_CD 5_CD 6_CD 7_CD 8_CD 9_CD ]_NN standard_JJ therapy_NN for_IN patients_NNS with_IN metastatic_JJ
        disease_NN remains_VBZ 5_CD -_: fluorouracil_NN (_( 5_CD -_: FU_NNP )_) -_: based_VBN chemotherapy_NN ._.
        [_NN 10_CD ]_NN A_DT vast_JJ series_NN of_IN pre-clinical_JJ and_CC clinical_JJ studies_NNS
        have_VBP suggested_VBN 5_CD -_: FU_NNP is_VBZ a_DT more_RBR active_JJ anti-tumor_JJ agent_NN when_WRB
        modulated_JJ by_IN a_DT host_NN of_IN compounds_NNS including_VBG leucovorin_NN ,_, [_NN 11_CD
        12_CD 13_CD ]_NN methotrexate_NN ,_, [_NN 14_CD ]_NN folinic_JJ acid_NN ,_, [_NN 15_CD 16_CD ]_NN
        N-_NNP phosphonacetyl-_NN L-_NNP aspartic_JJ acid_NN (_( PALA_NNP )_) [_NN 17_CD 18_CD 19_CD 20_CD 21_CD 22_CD
        ]_NN and_CC recombinant_JJ interferon_NN alfa-_NN 2_CD a_DT (_( IFNaα-_NNP 2_CD a_DT )_) ._. [_NN 23_CD 24_CD ]_NN
        Protracted_NNP venous_JJ infusion_NN (_( PVI_NNP )_) 5_CD -_: FU_NNP regimens_NNS have_VBP also_RB
        resulted_VBN in_IN increased_VBN response_NN rates_NNS in_IN some_DT studies_NNS ,_, but_CC
        only_RB results_VBZ in_IN a_DT modest_JJ benefit_NN in_IN median_JJ survival_NN ._. [_NN 25_CD
        26_CD ]_NN Oral_NNP fluoropyrimidines_NNS and_CC oral_JJ regimens_NNS using_VBG
        prodrugs_NNS of_IN 5_CD -_: FU_NNP or_CC inhibitors_NNS of_IN dihydropyrimidine_NN
        dehydrogenase_NN (_( DPD_NNP )_) which_WDT pharmacologically_RB simulate_VBP the_DT
        intravenous_JJ continuous_JJ infusion_NN administration_NN of_IN 5_CD -_: FU_NNP are_VBP
        currently_RB under_IN clinical_JJ evaluation_NN ._. Although_IN these_DT studies_NNS
        are_VBP important_JJ and_CC may_MD demonstrate_VB equivalency_NN ,_, it_PRP is_VBZ not_RB
        clear_VB these_DT oral_JJ compounds_NNS will_MD result_VB in_IN a_DT significant_JJ
        improvement_NN compared_VBN to_TO the_DT intravenous_JJ infusion_NN of_IN 5_CD -_: FU_NNP ._. [_NN
        27_CD ]_NN
        Potentiation_NNP of_IN the_DT anti-tumor_JJ activity_NN of_IN 5_CD -_: FU_NNP by_IN
        methotrexate_NN (_( MTX_NNP )_) and_CC leucovorin_NN (_( LV_NNP )_) requires_VBZ careful_JJ
        scheduling_NN to_TO achieve_VB the_DT most_RBS favorable_JJ interactions_NNS
        between_IN these_DT 3_CD drugs_NNS ._. In_IN vitro_NN and_CC in_IN vivo_NN studies_NNS have_VBP
        both_DT suggested_VBN a_DT synergistic_JJ as_IN well_RB as_IN antagonistic_JJ effect_NN
        when_WRB 5_CD -_: FU_NNP ,_, MTX_NNP and_CC LV_NNP are_VBP used_VBN in_IN combination_NN ._. [_NN 28_CD 29_CD 30_CD
        31_CD 32_CD ]_NN In_IN this_DT report_NN ,_, two_CD modulators_NNS of_IN 5_CD -_: FU_NNP were_VBD used_VBN in_IN
        a_DT sequential_NN manner_NN ,_, anticipating_VBG an_DT enhancement_NN of_IN the_DT
        efficacy_NN of_IN 5_CD -_: FU_NNP before_IN the_DT development_NN of_IN 5_CD -_: FU_NNP resistance_NN
        and_CC subsequent_JJ disease_NN progression_NN ._. The_DT order_NN of_IN
        administration_NN of_IN the_DT three_CD agents_NNS was_VBD chosen_VBN to_TO optimally_RB
        exploit_VB the_DT reported_VBD differing_VBG mechanisms_NNS of_IN biochemical_JJ
        modulation_NN ._. The_DT objectives_NNS of_IN this_DT phase_NN II_NNP study_NN were_VBD to_TO
        determine_VB the_DT activity_NN and_CC toxicity_NN of_IN MTX_NNP /_NN LV_NNP /_NN 5_CD -_: FU_NNP in_IN
        patients_NNS with_IN advanced_JJ colorectal_NN cancer_NN ._.
      
      
        Patients_NNS and_CC Methods_NNP
        
          Treatment_NNP Plan_NNP
          Consistent_NNP with_IN the_DT traditional_JJ design_NN of_IN phase_NN II_NNP
          studies_NNS ,_, all_DT patients_NNS received_VBD therapy_NN as_IN outlined_VBN in_IN the_DT
          treatment_NN schema_NN in_IN figure_NN 1_CD ._. Methotrexate_NNP was_VBD
          administered_VBN at_IN a_DT dose_NN of_IN 30_CD mg_NN /_NN m_NN 2_CD orally_RB every_DT 6_CD hours_NNS
          on_IN an_DT empty_JJ stomach_NN for_IN 6_CD doses_NNS ._. At_IN hour_NN 36_CD a_DT 2_CD hour_NN
          intravenous_JJ infusion_NN of_IN leucovorin_NN was_VBD administered_VBN at_IN a_DT
          dose_NN of_IN 500_CD mg_NN /_NN m_NN 2_CD ._. Midway_NNP through_IN the_DT leucovorin_NN
          infusion_NN ,_, 5_CD -_: FU_NNP at_IN a_DT dose_NN of_IN 600_CD mg_NN /_NN m_NN 2_CD was_VBD given_VBN as_IN a_DT 30_CD
          minute_NN intravenous_JJ bolus_JJ infusion_NN ._. This_DT represented_VBD a_DT
          course_NN of_IN therapy_NN and_CC was_VBD repeated_VBN every_DT two_CD weeks_NNS ._. Dose_NNP
          modifications_NNS for_IN hematologic_JJ toxicity_NN were_VBD made_VBN on_IN the_DT
          basis_NN of_IN counts_NNS on_IN the_DT day_NN of_IN treatment_NN ._. For_IN a_DT white_JJ
          blood_NN count_NN =_SYM 3_CD ,_, 500_CD cells_NNS /_NN ul_NN or_CC a_DT platelet_NN count_NN =_SYM
          100_CD ,_, 000_CD platelets_NNS /_NN ul_NN -_: patients_NNS received_VBD full_JJ doses_NNS of_IN
          all_DT three_CD drugs_NNS as_IN described_VBN above_IN ._. For_IN a_DT white_JJ blood_NN
          count_NN between_IN 3_CD ,_, 000_CD and_CC 3_CD ,_, 500_CD cells_NNS /_NN ul_NN and_CC a_DT platelet_NN
          count_NN =_SYM 100_CD ,_, 000_CD platelets_NNS /_NN ul_NN ,_, a_DT 50_CD %_NN dose_NN reduction_NN of_IN all_DT
          three_CD drugs_NNS was_VBD performed_VBN ._. For_IN white_JJ blood_NN counts_VBZ less_JJR
          than_IN 3_CD ,_, 000_CD cells_NNS /_NN ul_NN and_CC a_DT platelet_NN count_NN <_NN 100_CD ,_, 000_CD
          platelets_NNS /_NN ul_NN -_: all_DT therapy_NN was_VBD held_VBN until_IN the_DT counts_NNS had_VBN
          fully_RB recovered_VBN (_( white_JJ blood_NN count_NN =_SYM 3_CD ,_, 500_CD cells_NNS /_NN ul_NN and_CC a_DT
          platelet_NN count_NN =_SYM 100_CD ,_, 000_CD )_) ._. Patients_NNS experiencing_VBG a_DT white_JJ
          blood_NN count_NN =_SYM 2_CD ,_, 000_CD and_CC /_NN or_CC a_DT platelet_NN count_NN =_SYM 75_CD ,_, 000_CD any_DT
          time_NN during_IN therapy_NN subsequently_RB received_VBD 50_CD %_NN of_IN the_DT
          calculated_VBN dose_NN even_RB if_IN the_DT counts_NNS fully_RB recovered_VBN ._.
          Weekly_NNP complete_JJ blood_NN counts_VBZ ,_, including_VBG platelet_NN
          counts_VBZ and_CC white_JJ blood_NN count_NN differentials_NNS were_VBD conducted_VBN
          to_TO determine_VB the_DT level_NN of_IN myelosuppresion_NN ._. Before_IN every_DT
          other_JJ cycle_NN of_IN treatment_NN (_( q_NN 4_CD weeks_NNS )_) ,_, a_DT chest_NN x-ray_JJ and_CC
          complete_JJ chemistry_NN panel_NN including_VBG electrolytes_NNS and_CC serum_NN
          creatinine_NN were_VBD obtained_VBN ._. All_DT lesions_NNS were_VBD measured_VBN
          bidimensionally_RB and_CC assessed_VBN for_IN changes_NNS by_IN either_DT an_DT
          imaging_NN study_NN (_( computed_JJ tomography_NN ,_, chest_NN x-ray_JJ ,_,
          ultrasound_NN )_) or_CC by_IN clinical_JJ examination_NN to_TO determine_VB
          response_NN to_TO therapy_NN ._. Treatment_NNP was_VBD continued_VBN until_IN
          disease_NN progression_NN became_VBD evident_JJ or_CC side_NN effects_NNS became_VBD
          intolerable_JJ ._.
        
        
          Statistical_NNP Methods_NNP
          This_DT study_NN was_VBD planned_VBN to_TO recruit_VB 50_CD evaluable_JJ
          patients_NNS ,_, allowing_VBG us_PRP to_TO estimate_VB objective_NN tumor_NN
          response_NN to_TO within_IN +_NN /_NN -_: 15_CD %_NN with_IN 95_CD %_NN confidence_NN ._.
          Additional_JJ patients_NNS were_VBD subsequently_RB accrued_VBN to_TO increase_VB
          the_DT precision_NN of_IN our_PRP$ estimates_NNS of_IN response_NN and_CC survival_NN ._.
          The_DT trial_NN was_VBD conducted_VBN with_IN one_CD interim_JJ analysis_NN after_IN
          nine_CD evaluable_JJ patients_NNS ._. If_IN no_DT patient_NN had_VBD experienced_VBN an_DT
          objective_NN tumor_NN response_NN ,_, the_DT study_NN would_MD have_VB been_VBN
          terminated_VBN ._. The_DT two-stage_JJ design_NN used_VBN in_IN this_DT study_NN was_VBD
          first_RB proposed_VBN by_IN Ed_NNP Gehan_NNP in_IN 1961_CD (_( Gehan_NNP E_NNP ._. A_DT ._. The_DT
          determination_NN of_IN the_DT number_NN of_IN patients_NNS required_VBN in_IN a_DT
          preliminary_JJ and_CC a_DT follow-up_JJ trial_NN of_IN a_DT new_JJ
          chemotherapeutic_JJ agent_NN ._. J_NNP ._. Chron_NNP ._. Dis_NNP ._. 13_CD :_: 346_CD -_: 353_CD ,_, 1961_CD )_) ._.
          The_DT probability_NN of_IN observing_VBG no_DT responses_NNS was_VBD less_JJR than_IN
          5_CD %_NN if_IN the_DT true_JJ response_NN was_VBD 30_CD %_NN or_CC greater_JJR ._.
          Progression-free_NNP survival_NN was_VBD defined_VBN as_IN the_DT time_NN from_IN
          study_NN entry_NN to_TO the_DT first_JJ observation_NN of_IN disease_NN
          progression_NN or_CC death_NN as_IN a_DT result_NN of_IN any_DT cancer_NN ._. Survival_NNP
          was_VBD defined_VBN as_IN the_DT time_NN of_IN study_NN entry_NN until_IN death_NN as_IN a_DT
          result_NN of_IN any_DT cause_NN ._. These_DT time-to-event_JJ parameters_NNS were_VBD
          summarized_VBD using_VBG Kaplan-_NNP Meier_NNP product-limit_JJ estimates_NNS ._.
          Log_NNP rank_NN tests_NNS were_VBD used_VBN to_TO assess_VB which_WDT factors_NNS were_VBD
          univariately_RB predictive_JJ of_IN the_DT time_NN to_TO progression_NN and_CC
          survival_NN ,_, and_CC the_DT Cox_NNP proportional_JJ hazards_NNS regression_NN
          model_NN was_VBD used_VBN to_TO assess_VB which_WDT factors_NNS were_VBD jointly_RB
          predictive_JJ of_IN these_DT outcomes_NNS ._. The_DT statistical_JJ analysis_NN
          was_VBD performed_VBN using_VBG the_DT SAS_NNP package_NN ,_, version_NN 6_CD ._. 12_CD (_( SAS_NNP
          Institute_NNP ,_, Cary_NNP ,_, NC_NNP )_) ._.
        
      
      
        Results_NNS
        
          Treatment_NNP and_CC Response_NNP
          A_DT total_NN of_IN 1257_CD cycles_NNS of_IN treatment_NN were_VBD delivered_VBN
          during_IN the_DT trial_NN (_( median_JJ 9_CD cycles_NNS ;_: range_NN 0_CD to_TO 41_CD cycles_NNS )_) ._.
          Table_NNP 2_CD reflects_VBZ the_DT average_JJ percent_NN of_IN ideal_JJ dose_NN given_VBN
          at_IN each_DT selected_VBN cycle_NN of_IN treatment_NN ._. Even_RB after_IN 25_CD cycles_NNS
          of_IN therapy_NN ,_, at_IN least_JJS 75_CD %_NN of_IN the_DT ideal_JJ doses_NNS for_IN all_DT drugs_NNS
          were_VBD being_VBG administered_VBN ._. Ninety-three_NNP of_IN the_DT 95_CD eligible_JJ
          patients_NNS enrolled_VBD onto_IN the_DT study_NN were_VBD assessable_JJ for_IN
          toxicity_NN ._. Mucositis_NNP ,_, nausea_NN /_NN vomiting_NN and_CC diarrhea_NN were_VBD
          the_DT most_RBS commonly_RB observed_VBD toxicities_NNS and_CC are_VBP listed_VBN in_IN
          table_NN 3_CD ._. The_DT hematologic_JJ toxicities_NNS are_VBP also_RB shown_VBN in_IN
          table_NN 3_CD and_CC in_IN general_NN were_VBD infrequently_RB observed_VBN ._. Overall_RB
          the_DT regimen_NN was_VBD well_RB tolerated_JJ ._.
          Of_IN the_DT 90_CD patients_NNS evaluable_JJ for_IN response_NN ,_, ten_CD
          patients_NNS (_( 11_CD %_NN )_) demonstrated_VBD a_DT complete_JJ response_NN of_IN their_PRP$
          disease_NN (_( median_JJ response_NN duration_NN 14_CD ._. 3_LS months_NNS )_) ._.
          Remarkably_NNP ,_, 3_CD of_IN the_DT 10_CD patients_NNS remain_VBP alive_JJ ,_, 2_CD without_IN
          evidence_NN of_IN disease_NN with_IN 51_CD ,_, 73_CD and_CC 138_CD months_NNS of_IN
          follow-up_JJ ,_, respectively_RB ._. An_DT additional_JJ 18_CD patients_NNS (_( 20_CD %_NN )_)
          attained_VBN partial_JJ responses_NNS ;_: 16_CD have_VBP died_VBN of_IN progressive_JJ
          disease_NN while_IN 2_CD patients_NNS are_VBP alive_JJ and_CC without_IN disease_NN
          progression_NN ._. Table_NNP 4_CD reflects_VBZ the_DT overall_JJ best_JJS response_NN
          for_IN the_DT entire_JJ patient_NN cohort_NN ._.
          The_DT overall_RB estimated_VBN median_JJ time_NN to_TO progression_NN was_VBD
          5_CD ._. 6_CD months_NNS ._. The_DT estimated_VBN progression_NN free_JJ survival_NN at_IN 12_CD
          months_NNS was_VBD 25_CD ._. 5_LS %_NN (_( standard_JJ error_NN 4_CD ._. 5_CD %_NN )_) ._. The_DT overall_RB
          estimated_VBN median_JJ survival_NN time_NN was_VBD 13_CD ._. 0_CD months_NNS ._. The_DT
          estimated_VBN survival_NN rate_NN at_IN 12_CD months_NNS was_VBD 53_CD ._. 7_CD %_NN (_( standard_JJ
          error_NN 5_CD ._. 1_CD %_NN )_) ._. Table_NNP 5_CD reflects_VBZ overall_JJ survival_NN for_IN various_JJ
          subgroups_NNS of_IN patients_NNS ._. The_DT prognostic_JJ factors_NNS found_VBD to_TO be_VB
          significant_JJ on_IN univariate_NN analysis_NN were_VBD ECOG_NNP performance_NN
          score_NN ,_, gender_NN and_CC number_NN of_IN metastatic_JJ sites_NNS ._. Female_NNP
          patients_NNS ,_, patients_NNS with_IN fewer_RBR metastatic_JJ sites_NNS and_CC
          patients_NNS with_IN an_DT ECOG_NNP performance_NN 0_CD had_VBD a_DT statistically_RB
          significant_JJ improved_VBN survival_NN ._. Survival_NNP by_IN metastatic_JJ
          site_NN is_VBZ shown_VBN in_IN Table_NNP 6_CD ._. Those_DT patients_NNS without_IN lung_NN
          metastasis_NNS and_CC those_DT without_IN intra-abdominal_JJ metastasis_NNS
          had_VBD longer_JJR survival_NN times_NNS ._. In_IN the_DT multivariate_NN analysis_NN ,_,
          presence_NN of_IN lymph_NN nodes_NNS ,_, lower_JJR LDH_NNP levels_NNS female_JJ sex_NN ,_,
          better_JJR performance_NN status_NN and_CC fewer_RBR metastatic_JJ sites_NNS were_VBD
          statistically_RB predictive_JJ of_IN longer_JJR survival_NN (_( Data_NNP not_RB
          shown_VBN )_) ._.
        
      
      
        Discussion_NNP
        The_DT rationale_NN ,_, at_IN least_JJS in_IN part_NN ,_, for_IN this_DT phase_NN II_NNP study_NN
        comes_VBZ from_IN pre-clinical_JJ data_NNS suggesting_VBG MTX_NNP and_CC LV_NNP
        potentiate_NN the_DT anti-tumor_JJ activity_NN of_IN 5_CD -_: FU_NNP ._. The_DT cytotoxic_JJ
        effects_NNS of_IN 5_CD -_: FU_NNP are_VBP mediated_JJ through_IN inhibition_NN of_IN DNA_NNP
        and_CC /_NN or_CC RNA_NNP synthesis_NN ._. [_NN 33_CD ]_NN DNA_NNP synthesis_NN inhibition_NN is_VBZ
        mediated_JJ by_IN the_DT binding_VBG of_IN the_DT active_JJ 5_CD -_: FU_NNP metabolite_NN
        5_CD -_: fluoro-_NN 2_CD '_POS deoxyuridine_NN -_: 5_CD -_: monophosphate_NN (_( F-_NNP dUMP_NN )_) to_TO the_DT
        enzyme_NN thymidylate_NN synthetase_NN (_( TS_NNP )_) ._. This_DT binding_JJ is_VBZ
        enhanced_VBN by_IN high_JJ concentrations_NNS of_IN reduced_VBN folate_NN
        cofactors_NNS ._. [_NN 34_CD ]_NN Although_IN this_DT ternary_JJ complex_NN is_VBZ
        covalent_NN ,_, it_PRP dissociates_NNS with_IN a_DT half-life_NN of_IN 2_CD -_: 3_CD hours_NNS in_IN
        the_DT absence_NN of_IN excess_JJ 5_CD ,_, 10_CD -_: methylene_NN tetrahydrofolate_NN ._.
        Thus_RB high_JJ levels_NNS of_IN 5_CD ,_, 10_CD -_: methylene_NN tetrahydrofolate_NN
        derived_VBN from_IN LV_NNP not_RB only_RB allows_VBZ optimum_JJ ternary_JJ complex_JJ
        formation_NN ,_, but_CC also_RB prevents_VBZ subsequent_JJ breakdown_NN of_IN the_DT
        complex_NN ._. [_NN 35_CD ]_NN Additional_JJ in_IN vitro_NN studies_NNS suggest_VBP cells_NNS
        may_MD need_VB prolonged_JJ exposure_NN to_TO reduced_VBN folates_NNS in_IN order_NN to_TO
        obtain_VB maximum_NN inhibition_NN of_IN TS_NNP by_IN FdUMP_NNP ._. [_NN 36_CD ]_NN A_DT second_RB
        observed_VBD means_NNS of_IN potentiating_VBG the_DT cytotoxic_JJ effects_NNS of_IN
        5_CD -_: FU_NNP is_VBZ through_IN the_DT pre-treatment_JJ of_IN cells_NNS with_IN MTX_NNP ._.
        MTX-induced_NNP enhancement_NN of_IN 5_CD -_: phosphoribosyl-_NN 1_CD -_: pyrophosphate_NN
        (_( PRPP_NNP )_) pools_NNS with_IN subsequent_JJ increased_VBN synthesis_NN of_IN 5_CD -_: FU_NNP
        nucleotides_NNS and_CC incorporation_NN of_IN 5_CD -_: fluoriuridine_NN -_:
        5_CD '_POS -_: triphosphate_NN (_( FUTP_NNP )_) into_IN RNA_NNP has_VBZ been_VBN proposed_VBN as_IN the_DT
        basis_NN for_IN this_DT biochemical_JJ modulation_NN ._. [_NN 37_CD 38_CD 39_CD ]_NN
        Subsequent_JJ in_IN vivo_NN studies_NNS using_VBG fluorine_NN 19_CD magnetic_JJ
        resonance_NN spectroscopy_NN confirmed_VBD a_DT three-fold_JJ increase_NN in_IN
        5_CD -_: fluoronucleotide_NN (_( FNuct_NNP )_) ,_, the_DT active_JJ 5_CD -_: FU_NNP metabolite_NN ,_,
        following_VBG the_DT pre-treatment_JJ of_IN animals_NNS with_IN MTX_NNP [_NN 32_CD ]_NN ._.
        These_DT observed_VBD changes_NNS in_IN 5_CD -_: FU_NNP catabolism_NN resulted_VBD in_IN a_DT
        greater_JJR anti-tumor_JJ activity_NN than_IN MTX_NNP given_VBN alone_RB or_CC MTX_NNP
        given_VBN after_IN 5_CD -_: FU_NNP ._. Consistent_NNP with_IN these_DT pre-clinical_JJ
        studies_NNS ,_, the_DT design_NN of_IN this_DT phase_NN II_NNP trial_NN involved_VBD a_DT
        fluorouracil_NN infusion_NN that_WDT was_VBD initiated_VBN one_CD hour_NN into_IN the_DT
        2_CD hour_NN high_JJ dose_NN infusion_NN of_IN LV_NNP and_CC 36_CD hours_NNS after_IN the_DT
        initial_JJ methotrexate_NN dosing_VBG ._.
        Our_PRP$ phase_NN II_NNP study_NN provides_VBZ long-term_JJ efficacy_NN and_CC
        safety_NN data_NNS for_IN sequential_NN MTX-LV-_NNP 5_CD -_: FU_NNP chemotherapy_NN
        administered_VBN on_IN a_DT 14_CD -_: day_NN cycle_NN ._. The_DT 31_CD %_NN response_NN rate_NN and_CC
        median_JJ survival_NN duration_NN (_( median_JJ 13_CD ._. 0_CD months_NNS )_) observed_VBD in_IN
        this_DT trial_NN are_VBP slightly_RB improved_VBN when_WRB compared_VBN to_TO the_DT
        results_NNS reported_VBD for_IN intravenous_JJ 5_CD -_: FU_NNP therapy_NN ._. Overall_RB ,_,
        treatment_NN with_IN sequential_NN MTX-LV-_NNP 5_CD -_: FU_NNP was_VBD very_RB
        well-tolerated_JJ ._. Grade_NNP III_NNP diarrhea_NN was_VBD seen_VBN in_IN only_RB 8_CD %_NN of_IN
        patients_NNS ,_, grade_NN III_NNP and_CC IV_NNP mucositis_NNS in_IN 8_CD %_NN and_CC 1_CD %_NN of_IN
        patients_NNS respectively_RB and_CC grade_NN III_NNP and_CC IV_NNP nausea_NN /_NN vomiting_NN
        in_IN 11_CD %_NN and_CC 1_CD %_NN of_IN patients_NNS respectively_RB ._. The_DT most_RBS common_JJ
        hematologic_JJ toxicity_NN observed_VBD was_VBD grade_NN II_NNP and_CC III_NNP anemia_NN
        in_IN 18_CD %_NN and_CC 4_CD %_NN of_IN patients_NNS respectively_RB ._.
        Other_JJ similar_JJ studies_NNS have_VBP shown_VBN comparable_JJ results_NNS in_IN
        terms_NNS of_IN the_DT efficacy_NN and_CC safety_NN of_IN MTX-LV-_NNP 5_CD -_: FU_NNP for_IN
        patients_NNS with_IN advanced_JJ colorectal_NN cancer_NN [_NN 44_CD 45_CD 46_CD 47_CD 48_CD ]_NN
        ._. In_IN a_DT meta_NN analysis_NN of_IN eight_CD randomized_JJ trials_NNS of_IN 5_CD -_: FU_NNP /_NN MTX_NNP
        versus_CC 5_CD -_: FU_NNP alone_RB ,_, the_DT complete_JJ and_CC partial_JJ response_NN rates_NNS
        for_IN the_DT 5_CD -_: FU_NNP patient_NN cohort_NN was_VBD 10_CD %_NN compared_VBN with_IN 19_CD %_NN for_IN
        patients_NNS receiving_VBG MTX_NNP /_NN 5_CD -_: FU_NNP ._. [_NN 14_CD ]_NN In_IN addition_NN ,_, the_DT median_JJ
        survival_NN was_VBD improved_VBN for_IN patients_NNS receiving_VBG MTX_NNP /_NN 5_CD -_: FU_NNP ,_, 10_CD ._. 7_CD
        months_NNS versus_CC 9_CD ._. 1_CD months_NNS for_IN patients_NNS receiving_VBG 5_CD -_: FU_NNP alone_RB
        (_( 
        p_NN =_SYM ._. 024_CD )_) ._. Marsh_NNP et_CC al_NN ._. in_IN a_DT
        randomized_JJ trial_NN ,_, reported_VBD a_DT statistical_JJ improvement_NN in_IN
        response_NN ,_, time_NN to_TO progression_NN (_( 9_CD ._. 9_CD months_NNS versus_CC 5_CD ._. 9_CD
        months_NNS )_) and_CC median_JJ survival_NN (_( 15_CD ._. 3_LS months_NNS versus_CC 11_CD ._. 4_LS
        months_NNS )_) when_WRB the_DT interval_NN between_IN the_DT MTX_NNP and_CC 5_CD -_: FU_NNP infusion_NN
        was_VBD increased_VBN from_IN 1_CD hour_NN to_TO 24_CD hours_NNS ._.
      
      
        Conclusions_NNP
        We_PRP suggest_VBP our_PRP$ results_NNS and_CC the_DT pre-clinical_JJ and_CC clinical_JJ
        data_NNS discussed_VBN indicate_VBP the_DT sequence_NN of_IN administration_NN of_IN
        5_CD -_: FU_NNP with_IN MTX_NNP and_CC LV_NNP is_VBZ important_JJ ._. Future_JJ studies_NNS combining_VBG
        5_CD -_: FU_NNP with_IN other_JJ cytotoxic_JJ /_NN biologic_JJ compounds_NNS should_MD
        consider_VB the_DT mechanism_NN of_IN the_DT interaction_NN and_CC incorporate_VB
        that_DT information_NN into_IN the_DT design_NN of_IN the_DT trial_NN ._.
      
      
        Abbreviations_NNP
        5_LS -_: FU_NNP :_: 5_CD -_: fluorouracil_NN
        PALA_NNP :_: N-_NNP phosphonacetyl-_NN L-_NNP aspartic_JJ acid_NN
        IFNaα-_NNP 2_CD a_SYM :_: Interferon_NNP alfa-_NN 2_CD a_DT
        PVI_NNP :_: Protracted_NNP venous_JJ infusion_NN
        DPD_NNP :_: dihydropyrimidine_NN dehydrogenase_NN
        MTX_NNP :_: Methotrexate_NNP
        LV_NNP :_: Leucovorin_NNP
        ECOG_NNP :_: Eastern_NNP Cooperative_NNP Oncology_NNP
        F-_NNP dUMP_NN :_: 5_CD -_: fluoro-_NN 2_CD '_POS deoxyuridine_NN -_: 5_CD -_: monophosphate_NN
        TS_NNP :_: thymidylate_NN synthetase_NN
        PRPP_NNP :_: 5_CD -_: phosphoribosyl-_NN 1_CD -_: pyrophosphate_NN
        FUTP_NNP :_: 5_CD -_: fluoriuridine_NN -_: 5_CD '_POS -_: triphosphate_NN
        FNuct_NNP :_: 5_CD -_: fluoronucleotide_NN
      
      
        Authors_NNP '_'' Contributions_NNP
        DRW_NNP and_CC PS_NNP were_VBD involved_VBN in_IN the_DT original_JJ design_NN and_CC
        accrual_NN to_TO this_DT phase_NN II_NNP clinical_JJ trial_NN ._. The_DT manuscript_NN was_VBD
        prepared_VBN and_CC written_VBN by_IN SKT_NNP and_CC AWB_NNP ._. The_DT manuscript_NN was_VBD
        then_RB read_VB and_CC revised_VBN by_IN members_NNS of_IN the_DT Gastrointestinal_NNP
        Research_NNP Group_NNP at_IN Wake_NNP Forest_NNP University_NNP (_( SAM_NNP and_CC VH_NNP )_) ._. LDC_NNP
        wrote_VBD and_CC performed_VBD all_DT statistical_JJ analysis_NN and_CC
        preparation_NN of_IN the_DT data_NNS presented_VBN in_IN this_DT manuscript_NN ._.
      
    
  
